13D Filings
LAVA Therapeutics N.V.
Amendment
Ownership

9.00%

Total Shares

2,370,533

Issuer CIK

1840748

CUSIP

N51517105

Event Date

Sep 15, 2025

Accepted

Sep 18, 2025, 07:08 PM

Reporting Persons (6)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Versant Venture Capital VI, L.P.
Partnership
9.00%2,370,5332,370,5330
Versant Ventures VI GP, L.P.
Partnership
9.00%2,370,53302,370,533
Versant Ventures VI GP-GP, LLC
Other
9.00%2,370,53302,370,533
Versant Vantage I, L.P.
Partnership
2.00%532,870532,8700
Versant Vantage I GP, L.P.
Partnership
2.00%532,8700532,870
Versant Vantage I GP-GP, LLC
Other
2.00%532,8700532,870
Disclosure Items (3)

Security Title

Common Shares, par value Euro 0.12 per share

Issuer Name

LAVA Therapeutics N.V.

Issuer Address

Yalelaan 62, Utrecht, P7, 3584 CM

Solely on behalf of, and only to the extent that it relates to, the Reporting Persons, Item 4 of the Original Schedule 13D is hereby amended and supplemented by the addition of the following: The Reporting Persons have previously reserved the right and continue to reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional Common Shares or other securities of the Issuer, dispose of some or all of the Common Shares or other securities of the Issuer that it may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

Percentage of Class

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Number of Shares

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Transactions

On September 16, 2025, Versant VI sold 307,707 Common Shares at a weighted average price per share of $1.5332 for aggregate proceeds of approximately $471,773.30. On September 16, 2025, Vantage LP sold 192,293 Common Shares at a weighted average price per share of $1.5332 for aggregate proceeds of approximately $294,821.70. On September 17, 2025, Versant VI sold 362,806 Common Shares at a weighted average price per share of $1.4892 for aggregate proceeds of approximately $540,281.58. On September 17, 2025, Vantage LP sold 226,726 Common Shares at a weighted average price per share of $1.4892 for aggregate proceeds of approximately $337,634.66. On September 18, 2025, Versant VI sold 366,111 Common Shares at a weighted average price per share of $1.4418 for aggregate proceeds of approximately $527,858.84. On September 18, 2025, Vantage LP sold 228,791 Common Shares at a weighted average price per share of $1.4418 for aggregate proceeds of approximately $329,870.86.